Keyword: Crestor

Of 31 drugs the Chinese government listed for a pilot bidding program, multinational pharmas landed only two contracts.

The FDA is updating its citizen petition review policy to consider whether branded companies are filing the requests to delay generics competition.

BMS and Pfizer’s Eliquis and J&J and Bayer’s Xarelto will lead the pack in 2024, followed by Amgen’s Repatha, Novartis’ Entresto and J&J's Uptravi.

Texas spanked AstraZeneca as a repeat offender in announcing a pair of off-label marketing settlements.

Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.

AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.

With cash flow under pressure, AstraZeneca could struggle to live up to CEO Pascal Soriot's commitment to pay a generous dividend "today, tomorrow, and thereafter."

The 10 CV drugs we’re profiling here represent the best-sellers by global 2016 sales, excluding those that faced generic competition throughout the year.